A One-Time Intervention for Type 2 Diabetes

The DIAMOND (Tantalus) System is CE marked and available for commercial use. The DIAMOND II System is not CE marked currently.

Improved glucose levels

HbA1c reduction of 1% and sustained long term results

Free from insulin

Single reversible intervention,
no daily needles, minimal side effects

Weight loss

Sustained weight loss and lowered blood pressure

Mechanism of action

The small implanted DIAMOND device detects when eating begins, and automatically sends gentle pulse signals (gastric contractility modulation signals, or GCM) to the stomach muscles. As a result, the DIAMOND restores the physiological synchronization between food intake and natural hormone secretion, and lowers post meal glucose levels.1 Additionally, GCM signals cause an earlier satiation effect resulting in sustained weight loss.2

Read more

Clinical evidence

Over 300 patients have been treated with DIAMOND in clinical trials3, with up to three years observation. The trials have demonstrated that gastric contractility modulation using DIAMOND significantly reduces HbA1c in a durable manner.4,5,6,7 Clinical data has also demonstrated sustained reduction of weight and blood pressure.8,9

Learn more

Treating T2D with DIAMOND

DIAMOND is a one-time intervention treatment for patients with type 2 diabetes who are obese and refractory to oral medication. The DIAMOND device is implanted subcutaneously through a fully reversible, minimally invasive laparoscopic procedure in the upper left abdomen and is connected with three leads to the stomach. Using a wireless physician tablet, the device is then configured and checked periodically by the physician or a clinical associate. Apart from weekly wireless charging, the device is maintenance free and allows patients to lead an active lifestyle. Furthermore, no specific diet adaptation is required beyond standard guidelines for diabetic patients.

Read more

Centers of excellence

A growing number of clinics implant the DIAMOND device, including a number of renowned academic centers.

Centers of excellence

[1] Lebovitz HE, Yaniv I, Schwartz T, Zelewski M, et al. Treatment of patients with obese type 2 diabetes with Tantalus-DIAMOND® gastric contractility modulation: Normal tryiglycerides predict durable effect for at least 3 years. Horm Metab Res. 2015;47:456-62. [2] Ibid [3] As of August 2015; data on file. [4] Lebovitz HE, Yaniv I, et al, 2015. [5] Lebovitz HE, Ludvik B, Kozakowski J, et al. Gastric electrical stimulation treatment of type 2 diabetes: effects of implantation versus meal-mediated stimulation. A randomized blinded cross-over trial. Physiol Rep. 2015;3(7). [6] Bohdjalian A, Prager G, Rosak C, et al. Improvement in glycemic control in morbidly obese type 2 diabetic subjects by gastric stimulation. Obes Surg. 2009;19(9):1221-7. [7] Sanmiguel CP, Conklin JL, Cunneen SA, Barnett P, et al. Gastric electrical stimulation with the TANTALUS® system in obese type 2 diabetes patients: Effect on weight and glycemic control. J Diabetes Sci Technol. 2009;3:964-70. [8] Wong SK, Kong AP, Luk AO, Ozaki R, et al. A pilot study to compare meal-triggered gastric contractility modulation and insulin treatment in Chinese obese type 2 diabetes. Diabetes Technol Ther. 2015;17:283-90. [9] Lebovitz HE, Ludvik B, et al, 2015.